Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH. The inhibition of ANGPTL3 shows an important therapeutic approach in reducing LDL-C and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-12, Vol.12 (1), p.168
Main Authors: Sosnowska, Bożena, Adach, Weronika, Surma, Stanisław, Rosenson, Robert S, Banach, Maciej
Format: Article
Language:English
Subjects:
Amino acids
Atherosclerosis
Black people
Body fat
Cardiovascular disease
Cholesterol
Clinical medicine
Diabetes
Heart attacks
High density lipoprotein
Lipoproteins
Liver
Low density lipoprotein receptors
Metabolic disorders
Metabolism
Monoclonal antibodies
Musculoskeletal system
Mutation
Proteins
Review
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH. The inhibition of ANGPTL3 shows an important therapeutic approach in reducing LDL-C and triglycerides (TG) levels and, thus, is a potentially effective strategy in the treatment of FH. Evinacumab is a monoclonal antibody inhibiting circulating ANGPTL3, available under the trade name Evkeeza for the treatment of homozygous FH. It was reported that evinacumab is effective and safe in patients with homozygous and heterozygous FH, as well as resistant hypercholesterolemia and hypertriglyceridemia. This paper summarizes existing knowledge on the role of ANGPTL3, 4, and 8 proteins in lipoprotein metabolism, the findings from clinical trials with evinacumab, a fully human ANGPTL3 mAb, and the place for this new agent in lipid-lowering therapy.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12010168